抗体药物偶联物(ADC)连接基团的四种选择
免疫抗体药材偶联物(ADC)衔接基团的每种选购表面抗原*口服药治疗偶联物(antibody-drug conjugate,ADC)是用一些催化外链将兼有生物技术活性氧的小原子口服药治疗连入到单抗上,单抗最为媒体将小原子口服药治疗靶向药物运输物流到制定目标人体细胞中,
(4)使用短肽作为连接基团:基于多肽的连接基团被设计为在体循环中保持偶联物稳定性,并且使得细胞****可以在特定的酶切割下被释放出来。
cas:352305-38-5N3-SS-N3 叠氮-SS-叠氮
cas:1310827-27-0 N3-PEG3-SS-PEG3-N3 叠氮-三聚乙二醇-SS-三聚乙二醇-叠氮cas:2228857-32-5 N3-SS-propionic acid叠氮-SS-丙酸基
cas:2144777-72-8 N3-SS-PEG2-acid
cas:2243566-44-9 N3-SS-propionic NHS ester叠氮-SS-丙酸基-活化脂
cas:1807540-82-4 N3-SS-ethylalcohol叠氮-SS-乙醇
cas:352305-38-5N3-SS-N3 叠氮-SS-叠氮
cas:1310827-27-0 N3-PEG3-SS-PEG3-N3 叠氮-三聚乙二醇-SS-三聚乙二醇-叠氮cas:2144777-83-1 N3-PEG2-t-Butyl ester
cas:671802-00-9Hydroxy-PEG-t-butyl ester (PEG1-PEGn)
cas:287174-32-7Hydroxy-PEG-CH2CO2tBu (PEG1-PEGn)
cas:1820673-42-4Hydroxy-PEG2-PFP ester
cas:112724-27-3Hydroxy-PEG2-sulfonic acid
cas:56282-36-1HS-PEG3-OH
cas:1146245-73-9 Mal-PEG2-oxyaminecas:2055041-37-5 Mal-PEG1-Val-Cit-PABC-OHcas:2249935-92-8 Mal-PEG1-Val-Cit-PABC-PNPcas:1870916-87-2 MC-Val-Ala-PABcas:1639939-40-4 MC-Val-Ala-PAB-PNPcas:1951424-92-2 Fmoc-Ala-Ala-Asn(Trt)-OHcas:2098907-84-5 Acid-propionylamino-Val-Cit-OHcas:2055041-40-0 N3-PEG1-Val-Cit-PABC-OHcas:252378-67-9Boc-Aminooxy-PEG2-bromide
cas:1235514-18-7 Boc-aminooxy-PEG3-aminecas:1884578-00-0 Boc-Val-Ala-PAB-PNPcas:173323-22-3Bromoacetamide-PEG3-acetic acid
cas:932741-11-2Bromoacetamide-PEG3-alkyne
cas:1260139-70-5 Bromoacetamido-PEG4-NHScas:1698019-89-4 Bromoacetamide-PEG8-acidcas:1803279-86-8 DBCO-C4-SulfoNHS estercas:2055198-07-5 DBCO-Sulfo-PEG4-Maleimidecas:1394238-91-5 Fmoc-Val-Ala-PABcas:1394238-92-6 Fmoc-Val-Ala-PAB-PNP